Kosei HasegawaMDPhD
Olaparib(Kosei Hasegawa, MD, PhD)은 Ovary Cancer 표적 ADC로, Carcinoma, Ovarian Epithelial 영역에서 개발·상용화 중입니다. 작용기전: targeting Vβ6 and Vβ10 T-cell receptor. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 16.8% (ClinicalTrials.gov NCT03834519). 차별점: novel radiolabeling approach for [ 211 At]talazoparib and report its in vitro and in vivo evaluation.
Ovary Cancer
Carcinoma, Ovarian Epithelial
Discontinued
ADC YL205 in heavily pretreated platinum-resistant ovarian canc
at
linker-payload technologies
novel radiolabeling approach for [ 211 At]talazoparib and report its in vitro and in vivo evaluation
targeting Vβ6 and Vβ10 T-cell receptor
T-cell activation
apoptosis-related assays
biomarker for metabolic state, B-cell/TLS-associated immune features, and vulnerability to DNA damage-based t
downregulation of HRR-related genes (BRCA1/2 and RAD51) with the reduced recruitment of phosphorylated-RNA polymerase II (pSer2) to th
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Kosei HasegawaMDPhD
Olaparib(Kosei Hasegawa, MD, PhD)은 Ovary Cancer 표적 ADC로, Carcinoma, Ovarian Epithelial 영역에서 개발·상용화 중입니다. 작용기전: targeting Vβ6 and Vβ10 T-cell receptor. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 16.8% (ClinicalTrials.gov NCT03834519). 차별점: novel radiolabeling approach for [ 211 At]talazoparib and report its in vitro and in vivo evaluation.
Ovary Cancer
Carcinoma, Ovarian Epithelial
Discontinued
ADC YL205 in heavily pretreated platinum-resistant ovarian canc
at
linker-payload technologies
novel radiolabeling approach for [ 211 At]talazoparib and report its in vitro and in vivo evaluation
targeting Vβ6 and Vβ10 T-cell receptor
T-cell activation
apoptosis-related assays
biomarker for metabolic state, B-cell/TLS-associated immune features, and vulnerability to DNA damage-based t
downregulation of HRR-related genes (BRCA1/2 and RAD51) with the reduced recruitment of phosphorylated-RNA polymerase II (pSer2) to th
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.